Lindsay A Zilliox1, Sandra K Ruby1, Sujal Singh1, Min Zhan1, James W Russell2. 1. Department of Neurology, Maryland VA Healthcare System and University of Maryland, Baltimore, MD, USA. 2. Department of Neurology, Maryland VA Healthcare System and University of Maryland, Baltimore, MD, USA. Electronic address: JRussell@som.umaryland.edu.
Abstract
AIMS: Disagreement exists on effective and sensitive outcome measures in neuropathy associated with impaired glucose tolerance (IGT). Nerve conduction studies and skin biopsies are costly, invasive and may have their problems with reproducibility and clinical applicability. A clinical measure of neuropathy that has sufficient sensitivity and correlates to invasive measures would enable significant future research. METHODS: Data was collected prospectively on patients with IGT and symptomatic early neuropathy (neuropathy symptoms <2years) and normal controls. The seven scales that were examined were the Neuropathy Impairment Score of the Lower Limb (NIS-LL), Michigan Diabetic Neuropathy Score (MNDS), modified Toronto Clinical Neuropathy Scale (mTCNS), Total Neuropathy Score (Clinical) (TNSc), The Utah Early Neuropathy Scale (UENS), the Early Neuropathy Score (ENS), and the Neuropathy Disability Score (NDS). RESULTS: All seven clinical scales were determined to be excellent in discriminating between patients with neuropathy from controls without neuropathy. The strongest discrimination was seen with the mTCNS. The best sensitivity and specificity for the range of scores obtained, as determined by using receiver operating characteristic curves, was seen for the mTCNS followed by the TNSc. Most scales show a stronger correlation with measures of large rather than small fiber neuropathy. CONCLUSIONS: All seven scales identify patients with neuropathy. For the purpose of screening potential patients for a clinical study, the mTCNS followed by the TNSc would be most helpful to select patients with neuropathy. Published by Elsevier Inc.
AIMS: Disagreement exists on effective and sensitive outcome measures in neuropathy associated with impaired glucose tolerance (IGT). Nerve conduction studies and skin biopsies are costly, invasive and may have their problems with reproducibility and clinical applicability. A clinical measure of neuropathy that has sufficient sensitivity and correlates to invasive measures would enable significant future research. METHODS: Data was collected prospectively on patients with IGT and symptomatic early neuropathy (neuropathy symptoms <2years) and normal controls. The seven scales that were examined were the Neuropathy Impairment Score of the Lower Limb (NIS-LL), Michigan Diabetic Neuropathy Score (MNDS), modified Toronto Clinical Neuropathy Scale (mTCNS), Total Neuropathy Score (Clinical) (TNSc), The Utah Early Neuropathy Scale (UENS), the Early Neuropathy Score (ENS), and the Neuropathy Disability Score (NDS). RESULTS: All seven clinical scales were determined to be excellent in discriminating between patients with neuropathy from controls without neuropathy. The strongest discrimination was seen with the mTCNS. The best sensitivity and specificity for the range of scores obtained, as determined by using receiver operating characteristic curves, was seen for the mTCNS followed by the TNSc. Most scales show a stronger correlation with measures of large rather than small fiber neuropathy. CONCLUSIONS: All seven scales identify patients with neuropathy. For the purpose of screening potential patients for a clinical study, the mTCNS followed by the TNSc would be most helpful to select patients with neuropathy. Published by Elsevier Inc.
Authors: L Zilliox; A C Peltier; P A Wren; A Anderson; A G Smith; J R Singleton; E L Feldman; N B Alexander; J W Russell Journal: Neurology Date: 2011-03-22 Impact factor: 9.910
Authors: Dan Ziegler; Nikolaos Papanas; Andrey Zhivov; Stephan Allgeier; Karsten Winter; Iris Ziegler; Jutta Brüggemann; Alexander Strom; Sabine Peschel; Bernd Köhler; Oliver Stachs; Rudolf F Guthoff; Michael Roden Journal: Diabetes Date: 2014-02-26 Impact factor: 9.461
Authors: Jennifer S Gewandter; Joanna Brell; Guido Cavaletti; Patrick M Dougherty; Scott Evans; Lynn Howie; Michael P McDermott; Ann O'Mara; A Gordon Smith; Daniela Dastros-Pitei; Lynn R Gauthier; Simon Haroutounian; Matthew Jarpe; Nathaniel P Katz; Charles Loprinzi; Paul Richardson; Ellen M Lavoie-Smith; Patrick Y Wen; Dennis C Turk; Robert H Dworkin; Roy Freeman Journal: Neurology Date: 2018-07-27 Impact factor: 9.910
Authors: Kelly G Gwathmey; Reza Sadjadi; William B Horton; Mark R Conaway; Carolina Barnett-Tapia; Vera Bril; James W Russell; Aziz Shaibani; Michelle L Mauermann; Michael K Hehir; Noah Kolb; Jeffrey Guptill; Lisa Hobson-Webb; Karissa Gable; Shruti Raja; Nicholas Silvestri; Gil I Wolfe; A Gordon Smith; Rabia Malik; Rebecca Traub; Amruta Joshi; Matthew P Elliott; Sarah Jones; Ted M Burns Journal: Neurology Date: 2018-05-04 Impact factor: 9.910
Authors: Jennifer S Gewandter; Laurie Burke; Guido Cavaletti; Robert H Dworkin; Christopher Gibbons; Tony D Gover; David N Herrmann; Justin C Mcarthur; Michael P McDermott; Bob A Rappaport; Bryce B Reeve; James W Russell; A Gordon Smith; Shannon M Smith; Dennis C Turk; Aaron I Vinik; Roy Freeman Journal: Muscle Nerve Date: 2016-12-23 Impact factor: 3.217
Authors: Brian C Callaghan; Rong Xia; Evan Reynolds; Mousumi Banerjee; Charles Burant; Amy Rothberg; Rodica Pop-Busui; Emily Villegas-Umana; Eva L Feldman Journal: Clin Neurophysiol Date: 2018-01-16 Impact factor: 3.708